Nanoshells for drug delivery
Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.
1. A nano-construct comprising
(a) a metal or metal alloy nanoshell formed around a core material, and
(b) a bioactive agent,
wherein the core material comprises a material selected from the group consisting of a liposome, a polymersome, and a hybrid vesicle comprising both lipid and polymer-based constituents,
wherein the core material further comprises dielectric material, which comprises magnetic ceramic particles.
2. The nano-construct of claim 1 , wherein the nanoshell is a gold nanoshell.
3. The nano-construct of claim 1 , comprising a large unilamellar vesicle,
wherein the large unilamellar vesicle encapsulates the nanoshell and the bioactive agent.
4. The nano-construct of claim 1 , wherein the core material is a small unilamellar vesicle encapsulating the bioactive agent.
5. The nano-construct of claim 1 , wherein the nanoshell is a gold nanoshell having a thickness in the range between about 5 and about 25 nm.
6. The nano-construct of claim 1 , wherein the core material is a liposome having a size in the range between about 150 nm to about 200 nm.
7. The nano-construct of claim 1 , wherein the metal or metal alloy nanoshell surrounding the core is porous to the bioactive agent once it is released from the core material.
8. The nano-construct of claim 2 , wherein the gold nanoshell surrounds the core of a dielectric material, and
wherein a plurality of these gold shells are conjugated to the surface of the core material, which contains the bioactive agent.
9. The nano-construct of claim 1 , wherein the core material comprises a peptide, a protein, or a combination of these.
10. The nano-construct of claim 1 , further comprising a targeting molecule on the surface of the nano-construct.
11. The nano-construct of claim 10 , wherein the targeting molecule is a surface-conjugated ligand against one or more receptors on an inflamed endothelium.
12. The nano-construct of claim 1 in a formulation suitable for systemic delivery or local delivery into a human being.
13. The nano-construct of claim 12 , wherein the systemic delivery is injection.
14. The nano-construct of claim 12 , wherein the local delivery is delivery by a device comprising a catheter.
15. The nano-construct of claim 1 , wherein the bioactive agent is paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl, tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin, γ-hirudin, clobetasol, pimecrolimus, imatinib mesylate, or midostaurin, or prodrugs, or combinations of these.
16. A method of forming a nano-construct according to claim 1 , comprising:
providing a core material selected from a liposome, a polymerosome, a hybrid vesicle,
forming a nanoshell around the core material.
17. The method of claim 16 , wherein the core material encapsulates a bioactive agent.
18. The method of claim 16 , wherein the formed nanoshell has porosity.
19. The method of claim 16 , wherein the core material is a liposome.
20. The method of claim 16 , wherein the nanoshell is a gold nanoshell having a thickness in the range between about 5 and about 25 nm.
21. The method of claim 16 , wherein the liposome has a size in the range between about 150 nm to about 200 nm.
22. The method of claim 16 , wherein the core material comprises a peptide, a protein, or a combination of these.
23. The method of claim 16 , wherein the nano-construct comprises a targeting molecule on the surface of the nano-construct.
24. The method of claim 23 , wherein the targeting molecule is a suface-conjugated ligand against receptors on an inflamed endothelium.
25. The method of claim 16 , wherein the nano-construct is in a formulation suitable for systemic delivery or local delivery into a human being.
26. The method of claim 25 , wherein the systemic delivery is injection.
27. The method of claim 25 , wherein the local delivery is delivery by a device comprising a catheter.
28. The method of claim 16 , wherein the bioactive agent is paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl, tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin, γ-hirudin, clobetasol, pimecrolimus, imatinib mesylate, or midostaurin, or prodrugs, or combinations of these.